PentaBind, shortlisted by Cancer Research UK as New Startup of the Year, is a cutting-edge AI aptamer drug discovery firm that recently saved 38 years of manual drug design time. It is now awaiting imminent results on the next generation of aptamer drugs that have huge applications in cancer and other diseases.